Related Experiment Video
Updated: Jan 6, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
A new frontier in oncology: Understanding the landscape of cancer vaccines
Tarun Kumar Suvvari1,2,3, Keshavi Killi1,4, Shreya Veggalam1,5
1Department of Research & Development, Squad Medicine and Research (SMR), Amadalavalasa, Andhra Pradesh, India.
Abstract:
Cancer vaccines represent a transformative shift in oncology, aiming to prevent malignancies or treat established cancers by training the immune system to recognize tumor-specific or tumor-associated antigens. This review explores the diverse platforms and mechanisms supporting cancer vaccines, ranging from prophylactic vaccines such as HPV and hepatitis B vaccines that have significantly reduced virus-related cancers to therapeutic vaccines like Sipuleucel-T and T-VEC that extend survival in prostate cancer and melanoma. Vaccine types are classified, and delivery platforms including mRNA, peptide, dendritic cell and viral vector-based approaches are examined alongside pivotal clinical trial outcomes. Key barriers to vaccine efficacy include tumor immune evasion, heterogeneity and the suppressive tumor microenvironment; combination therapies with checkpoint inhibitors or chemotherapy are evaluated for their potential to overcome these challenges. Despite promising trials, challenges persist in neoantigen selection, biomarker development, regulatory approval and scalable vaccine manufacturing. Data on current global utilization, approved indications and coverage disparities particularly in low and middle-income countries are presented. Furthermore, the cancer vaccine market is segmented by disease type, platform technology and region, with rising investments in personalized mRNA platforms and combined immunotherapies driving growth. In conclusion, cancer vaccines offer a less toxic, more precise approach to cancer prevention and treatment. Continued innovation, global collaboration, and infrastructure development are essential to realizing their full potential in improving patient outcomes and reducing the global cancer burden.
Insights
Cancer vaccines, including prophylactic and therapeutic types, train the immune system to fight cancer. Despite challenges like tumor evasion, advancements in platforms like mRNA offer a less toxic, precise approach to cancer prevention and treatment.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Cancer vaccines represent a paradigm shift in oncology, aiming to prevent or treat malignancies by eliciting an immune response against tumor antigens.
- Prophylactic vaccines (e.g., HPV, Hepatitis B) have reduced virus-related cancers, while therapeutic vaccines (e.g., Sipuleucel-T, T-VEC) show promise in extending survival for established cancers like prostate cancer and melanoma.
Purpose of the Study:
- To review diverse cancer vaccine platforms and mechanisms, including prophylactic and therapeutic strategies.
- To examine vaccine types, delivery platforms (mRNA, peptide, dendritic cell, viral vector), and clinical outcomes.
- To identify barriers to efficacy, evaluate combination therapies, and discuss market trends and global utilization.
Main Methods:
- Literature review and analysis of diverse cancer vaccine platforms and delivery systems.
- Classification of vaccine types and examination of clinical trial outcomes.
- Assessment of challenges, combination therapies, market segmentation, and global utilization data.
Main Results:
- Cancer vaccines, utilizing platforms like mRNA, peptide, dendritic cell, and viral vectors, demonstrate potential in preventing and treating various cancers.
- Key challenges include tumor immune evasion, heterogeneity, and the tumor microenvironment, often necessitating combination therapies with checkpoint inhibitors or chemotherapy.
- Despite ongoing hurdles in neoantigen selection and manufacturing, the cancer vaccine market is growing, driven by personalized mRNA platforms and immunotherapies.
Conclusions:
- Cancer vaccines offer a less toxic, more precise therapeutic strategy for cancer prevention and treatment.
- Overcoming barriers through continued innovation, global collaboration, and infrastructure development is crucial for maximizing their potential.
- Realizing the full impact of cancer vaccines requires addressing global disparities in access and manufacturing scalability.
More Related Videos
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:21Cancer Survival Analysis
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...